<DOC>
	<DOC>NCT00332696</DOC>
	<brief_summary>To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with peritoneal carcinomatosis</brief_summary>
	<brief_title>Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Intestinal Obstruction</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients with symptoms and signs of inoperable bowel obstruction confirmed by a surgeon or clinic and radiographic assessment (CT scan or at least abdominal Xray); Confirmed peritoneal carcinomatosis (with one of the following criteria : surgery, imaging and/or cytology); No corticotherapy at dose more than 1mg/kg equivalentmethylprednisolone, in the previous 2 weeks ; No chemotherapy in the previous week; No radio or chemotherapy planned at the inclusion and within the two weeks following inclusion Authorized concomitant treatments for local standard medical care : antiemetics, antispasmodics, antiHistamine2 (H2) drugs blockers or proton pump inhibitor, analgesics; nasogastric tube Abnormal coagulation (prothrombin time &lt; 60%, platelets &lt; 50x10^9/L). Non authorized concomitant treatments : 1. Anticholinergics such as scopolamine 2. Other somatostatin analogues Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>bowel obstruction,</keyword>
	<keyword>peritoneal carcinomatosis</keyword>
	<keyword>Octreotide</keyword>
	<keyword>inoperable</keyword>
</DOC>